The importance of pertussis in older adults: A growing case for reviewing vaccination strategy in the elderly

Vaccine

Volumn 30, Issue 48, 2012, Pages 6745-6752

  Ridda, Iman ^a,b   Yin, Jiehui Kevin ^b,c   King, Catherine ^b   Raina MacIntyre, C ^a   McIntyre, Peter ^b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Bordetella pertussis; Elderly vaccination; Pertussis; Whooping cough

Indexed keywords

PERTUSSIS VACCINE;

EMBASE; HEALTH CARE POLICY; HUMAN; IMMUNOGENICITY; MEDLINE; PERTUSSIS; PRIORITY JOURNAL; REVIEW; SAFETY; VACCINATION;

AGED; AGED, 80 AND OVER; BORDETELLA PERTUSSIS; HEALTH POLICY; HUMANS; MIDDLE AGED; VACCINATION; WHOOPING COUGH;

EID: 84868199323     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.079     Document Type: Review

References (81)

1. Zepp F., Heininger U., Mertsola J., Bernatowska E., Guiso N., Roord J., et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis 2011, 11(July (7)):557-570.
2. Ward J.I., Cherry J.D., Chang S-J., Partridge S., Lee H., Treanor J., et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005, 353(15):1555-1563.
3. Van Damme P., McIntyre P., Grimprel E., Kuriyakose S., Jacquet J.M., Hardt K., et al. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(R)) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine 2011, 29(August (35)):5932-5939.
4. Quinn H.E., McIntyre P.B. Pertussis epidemiology in Australia over the decade 1995-2005 - trends by region and age group. Commun Dis Intell 2007, 31(2):205-215.
5. World Health Organization. WHO immunisation schedule. World Health Organization immunization policy: global programme for vaccines and immunization - expanded programme on immunization. WHOGPV/GEN/95.03 Rev.1.; 1996.
6. Wall R., Bell A., Theobald J. Pertussis (whooping cough) epidemiology in Waikato, New Zealand: 2000-2009. NZ Med J 2011, 124(April (1332)):52-61.
7. Begg K., Roche P., Owen R., Liu C., Kaczmarek M., Hii A., et al. Australia's notifiable diseases status, 2006: annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2008, 32(June (2)):139-207.
8. Wright S.W., Edwards K.M., Decker M.D., Zeldin M.H. Pertussis infection in adults with persistent cough. JAMA 1995, 273(April (13)):1044-1046.
9. Nenning M., Shinefield H., Edwards K., Black S., Fireman B. Prevalence and incidence of adult pertussis in an urban population. JAMA 1996, 275:1672-1674.
10. Topinkova E.M.V. Tetanus and pertussis vaccines: their usefulness in the aging population. Aging Clin Exp Res 2009, 21(3):229-235.
11. Scheil W., Cameron S., Roberts C., Hall R. Pertussis in South Australia 1893 to 1996. Commun Dis Intell 1998, 22(May (5)):76-80.
12. Addiss D.G., Davis J.P., Meade B.D., Burstyn D.G., Meissner M., Zastrow J.A., et al. A pertussis outbreak in a Wisconsin nursing home. J Infect Dis 1991, 164(October (4)):704-710.
13. Mertens P.L.B.G., Richardus J.H. A pertussis outbreak associated with social isolation among elderly nuns in a convent. Clin Infect Dis 2007, 44(2):266-268.
14. Mink C.M., Cherry J.D., Christenson P., Lewis K., Pineda E., Shlian D., et al. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992, 14(February (2)):464-471.
15. Strebel P., Nordin J., Edwards K., Hunt J., Besser J., Burns S., et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001, 183(May (9)):1353-1359.
16. De Serres G.S.R., Duval B., Boulianne N., Dery P., Douville Fradet M., Rochette L., et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000, 182(1):174-179. 20000828 DCOM-20000828.
17. Crowcroft N., Stein C., Duclos P., Birmingham M. How best to estimate the global burden of pertussis. Lancet Infect Dis 2003, 3(7):413-418.
18. De Serres G., Shadmani R., Duval B., Boulianne N., Déry P., Douville Fradet M., et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000, 182(1):174-179.
19. Crowcroft N., Booy R., Harrison T., Spicer L., Britto J., Mok Q., et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child 2003, 88:802-806.
20. Rendi-Wagner P., Tobias J., Moerman L., Goren S., Bassal R., Green M., et al. The seroepidemiology of Bordetella pertussis in Israel - Estimate of incidence of infection. Vaccine 2010, 28(April (19)):3285-3290.
21. Riffelmann M., Littmann M., Hulsse C., O'Brien J., Wirsing von Konig C.H. Pertussis: incidence, symptoms and costs. Dtsch Med J 2006, 131(December (50)):2829-2834.
22. Thomas PF MP, Jalaludin B.B. Survey of pertussis morbidity in adults in western Sydney. Med J Aust 2000, 173(2):74-76.
23. Mertens P.L., Stals F.S., Schellekens J.F., Houben A.W., Huisman J. An epidemic of pertussis among elderly people in a religious institution in the Netherlands. Eur J Clin Microbiol Infect Dis 1999, 18(April (4)):242-247.
24. Lasserre A., Laurent E., Turbelin C., Hanslik T., Blanchon T., Guiso N. Pertussis incidence among adolescents and adults surveyed in general practices in the Paris area, France, May 2008 to March 2009. Euro Surveill 2011, 16(5).
25. O'Brien J., Caro J.J. Hospitalization for pertussis: profiles and case costs by age. BMC Infect Dis 2005, 5(1):57.
26. Rosenthal S., Strebel P., Cassiday P., Sanden G., Brusuelas K., Wharton M. Pertussis infection among adults during the 1993 outbreak in Chicago. J Infect Dis 1995, 171(June (6)):1650-1652.
27. Elomaa A., He Q., Minh N.N., Mertsola J. Pertussis before and after the introduction of acellular pertussis vaccines in Finland. Vaccine 2009, 27(September (40)):5443-5449.
28. Centers for Disease Control and Prevention Pertussis outbreak - Vermont, 1996. MMWR Morb Mortal Wkly Rep 1997, 46(September (35)):822-826.
29. Bonhoeffer J., Bar G., Riffelmann M., Soler M., Heininger U. The role of Bordetella infections in patients with acute exacerbation of chronic bronchitis. Infection 2005, 33(February (1)):13-17.
30. Wilder-Smith A., Earnest A., Ravindran S., Paton N.I. High incidence of pertussis among Hajj pilgrims. Clin Infect Dis 2003, 37(November (9)):1270-1272.
31. Antico A., Fabozzi F., Scipiotti C. Pertussis in adults. A study in an Italian population with chronic cough. Monaldi Arch Chest Dis 2002, 57(October-December (5-6)):247-252.
32. Gil A., Oyaguez I., Carrasco P., Gonzalez A. Hospital admissions for pertussis in Spain, 1995-1998. Vaccine 2001, 19(September (32)):4791-4794.
33. Muller-Pebody B., Crowcroft N.S., Zambon M.C., Edmunds W.J. Modelling hospital admissions for lower respiratory tract infections in the elderly in England. Epidemiol Infect 2006, 134(December (6)):1150-1157.
34. World Health Organization (WHO). Immunization surveillance, assessment and monitoring. ; 2011. http://www.who.int/immunization_monitoring/data/data_subject/en/index.html.
35. Durrheim D., Massey P., Carr C., Islam F. The changing epidemiology of pertussis in the Hunter New England area and potential implications for the immunisation schedule. NSW Public Health Bull 2006, 17(4):48-51.
36. Cherry J.D. The Epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005 2005, 115(May (5)):1422-1427.
37. Al-Murieb A.B.A., Raulli A., George C., Gander C., Forrester P., Gibson S. Evidence of pertussis clusters in three aged-care facilities in the former Macquarie Area Health Service, NSW. NSW Public Health Bull 2008, 19(9-10):157-160.
38. Volk V.K G.R., Anderson H.D., Top F.H., Bunney W.E., Serfling R.E. Antibody response to booster dose of diphtheria and tetanus toxoids and pertussis vaccine. Public Health Rep 1964, 79:424-434.
39. Maletto B A., Moron G., Cristina Pistoresi-Palencia M. Innate immune system modulation during aging: contributions of macrophages and dendritic cells. Curr Immunol Rev 2010, 6(4):329-338.
40. Herndler-Brandstetter D., Cioca D.P., Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise?. Wien Med Wochenschr (1946) 2006, 156(March (5-6)):130-141.
41. Kaml M.W.I., Keller M., Luft T., Hoster E., Hasford J., Young L., et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine 2006, 24(47-48).
42. Ntezayabo B., De Serres G., Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003, 22(January (1)):22-27.
43. Wood N., McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev 2008, 9(September (3)). 201-11; quiz 11-2.
44. Wendelboe A., Van R., Salmaso S., Englund J. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24. S58-S61.
45. Cagney M., MacIntyre C.R., McIntyre P., Puech M., Giammanco A. The seroepidemiology of pertussis in Australia during an epidemic period. Epidemiol Infect 2006, 134(December (6)):1208-1216.
46. Rothstein E., Edwards K. Health burden of pertussis in adolescents and adults. PIDJ 2005, 24(5). S44-S7.
47. Farizo K.M., Cochi S.L., Zell E.R., Brink E.W., Wassilak S.G., Patriarca P.A. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis 1992, 14(March (3)):708-719.
48. Zielinski A., Czarkowski M.P. Infectious diseases in Poland in 2007. Przegl Epidemiol 2009, 63(2):161-167.
49. Centers for Disease Control and Prevention Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006, 55. No. RR-17.
50. Skowronski D.M P.K., Remple V.P., Halperin B.A., Patrick D.M., Naus M., McIntyre C. Adult tetanus, diphtheria and pertussis immunization: knowledge, beliefs, behavior and anticipated uptake. Vaccine 2004, 23(3):353-361.
51. Barreto L., Guasparini R., Meekison W., Noya F., Young L., Mills E. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 2007, 25(November (48)):8172-8179.
52. Edelman K., He Q., Makinen J., Sahlberg A., Haanpera M., Schuerman L., et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007, 44(May (10)):1271-1277.
53. Hallander H.O., Gustafsson L., Ljungman M., Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine 2005, 23(November (46-47)):5359-5364.
54. Halperin S.A., Scheifele D., De Serres G., Noya F., Meekison W., Zickler P., et al. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine 2012, 30(January (5)):974-982.
55. Booy R., Van der Meeren O., Ng S.P., Celzo F., Ramakrishnan G., Jacquet J.M. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix) is immunogenic and well tolerated in adults. Vaccine 2010, 29(December (1)):45-50.
56. Van Rie A.H.H. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 2004, 22(23-24):3154-3165.
57. Isahak I. Adult immunization - a neglected issue in Southeast Asia. Southeast Asian J Trop Med Public Health 2000, 31(March (1)):173-184.
58. McIntyre P.B., Burgess M.A., Egan A., Schuerman L., Hoet B. Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine 2009, 27(February (7)):1062-1066.
59. Viney K.A., McAnulty J.M., Campbell-Lloyd S. Pertussis in New South Wales, 1993-2005: the impact of vaccination policy on pertussis epidemiology. NSW Public Health Bull 2007, 18(March-April (3-4)):55-61.
60. Schilling J., Duvoisin N., Lee C.Y., Naguel C., Gyurech D., Gutzwiller F. Childhood immunisation recall in Swiss employees. J Occup Health 2002, 44(1):40-45.
61. Beytout J., Launay O., Guiso N., Fiquet A., Baudin M., Richard P., et al. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin 2009, 5(May (5)):315-321.
62. Coudeville L., Van Rie A., Getsios D., Caro J.J., Crepey P., Nguyen V.H. Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS One 2009, 4(7):e6284.
63. Westra T.A., de Vries R., Tamminga J.J., Sauboin C.J., Postma M.J. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin Ther 2010, 32(August (8)):1479-1495.
64. Eickhoff T.C. Adult immunizations: how are we doing?. Hosp Pract 1996, 31(November (11)):107-117.
65. Shapiro-Shapin C.G., Pearl Kendrick Grace Eldering, and the pertussis vaccine. Emerg Infect Dis 2010, 16(August (8)):1273-1278.
66. Seale A., Finn A. What is the best way to use conjugate vaccines?. Curr Opin Infect Dis 2011, 24(June (3)):219-224.
67. Chen W.H., Kozlovsky B.F., Effros R.B., Grubeck-Loebenstein B., Edelman R., Sztein M.B. Vaccination in the elderly: an immunological perspective. Trends Immunol 2009, 30(July (7)):351-359.
68. de Melker H.E.V.F., Schellekens J.F., Teunis P.F., Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect 2006, 53(2):106-113.
69. Kuehn B.M. Panel backs wider pertussis vaccination to curb outbreaks, prevent deaths. JAMA 2010, 304(24):2684-2686.
70. Higginbotham T.W.C.K. Decreasing childhood pertussis infection through vaccination of the elderly. Cons Pharm 2008, 23(12):979-981.
71. Curran M.P., Leroux-Roels I. Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly. Drugs 2010, 70(August (12)):1519-1543.
72. Gardner P. Indications for acellular pertussis vaccines in adults: the case for selective, rather than universal, recommendations. Clin Infect Dis 1999, 28(June (Suppl. 2)):S131-S135.
73. Bisgard K.M., Pascual F.B., Ehresmann K.R., Miller C.A., Cianfrini C., Jennings C.E., et al. Infant pertussis: who was the source?. Pediatr Infec Dis J 2004, 23(11):985-989. 20041116DCOM-20050106.
74. Michel J-P. Updated vaccine guidelines for aging and aged citizens of Europe. Expert Rev Vaccines 2010, 9(3 Suppl.):7-10.
75. Michel J-P., Chidiac C., Grubeck-Loebenstein B., Johnson R.W., Lambert P.H., Maggi S., et al. Coalition of advocates to vaccinate of Western European citizens aged 60 years and older. Aging Clin Exp Res 2009, 21(3):254-257.
76. Michel J-P., Chidiac C., Grubeck-Loebenstein B., Johnson R.W., Lambert P.H., Maggi S., et al. Advocating vaccination of adults aged 60 years and older in Western Europe: statement by the Joint Vaccine Working Group of the European Union Geriatric Medicine Society and the International Association of Gerontology and Geriatrics-European Region. Rejuvenation Res 2009, 12(2):127-135.
77. Hofmann F. Vaccinations in adults-who? when? why?. Internist 2005, 46(2):206-213.
78. The Food and Drug Administration (FDA). Vaccines, blood & biologics - Boostrix. ; 2011. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172925.htm.
79. Nitsch-Osuch A., Gyrczuk E.W.A., Topczewska-Cabanek A., Zycińska K., Wardyn K.A. Knowledge of medical students concerning vaccinations in adults. Fam Med Primary Care Rev 2008, 10(2):180-185.
80. Bader M.S. Immunization for the elderly. Am J Med Sci 2007, 334(December (6)):481-486.
81. Campbell P., McIntyre P., Quinn H., Hueston L., Gilbert G.L., McVernon J. Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia. PLoS One 2012, 7(4):e35874.